AR033620A1 - Compuestos de sulfonilo de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen - Google Patents

Compuestos de sulfonilo de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
AR033620A1
AR033620A1 ARP020101090A ARP020101090A AR033620A1 AR 033620 A1 AR033620 A1 AR 033620A1 AR P020101090 A ARP020101090 A AR P020101090A AR P020101090 A ARP020101090 A AR P020101090A AR 033620 A1 AR033620 A1 AR 033620A1
Authority
AR
Argentina
Prior art keywords
branched
linear
group
nitrogen
alkyl group
Prior art date
Application number
ARP020101090A
Other languages
English (en)
Inventor
Nanteuil Guillaume De
Bernard Portevin
Alain Benoist
Nigel Levens
Olivier Nosjean
Bernadette Husson-Robert
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR033620A1 publication Critical patent/AR033620A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuesto de la formula (1) en la cual el ciclo A representa un heterociclo que contiene nitrogeno de cinco miembros, opcionalmente sustituido por un grupo ciano, R1 representa un átomo de hidrogeno o un grupo alquilo (C1-6) lineal o ramificado, acilo (C1-6) lineal o ramificado, propilo, alanilo, histidilprolilo o fenilalanilprolilo; Ak representa una cadena de alquileno (C1-6) lineal o ramificada o una cadena de heteroalquileno; X representa un unico enlace o un grupo fenileno opcionalmente sustituido por uno o más grupos idénticos o diferentes, seleccionados entre átomos de halogeno y grupos alquilo (C1-6) lineal o ramificado, hidroxi, alcoxi (C1-6) lineal o ramificado y polihaloalquilo (C1-6) lineal o ramificado; R2 representa un grupo alquilo (C1-6) lineal o ramificado (opcionalmente sustituido por uno o más grupos idénticos o diferentes, seleccionados entre arilo, alquilsulfonilo (C1-6) lineal o ramificado, cicloalquilsulfonilo (C3-7), grupo cicloalquilo (C3-7) y átomos de halogeno), un grupo cicloalquilo (C3-10), o -NR2aR2b en la cual R2a y R2b, que pueden ser iguales o diferentes, cada uno representa un átomo de hidrogeno o grupo alquilo (C1-6) lineal o ramificado, o junto con el átomo de nitrogeno que los contiene, forman un heterociclo que contiene nitrogeno, Y representa un grupo -NR3-, o de formulas (2) (3) o (4), R3 representa un átomo de hidrogeno o un grupo seleccionado entre el grupo alquilo (C1-6) lineal o ramificado, cicloalquilo (C3-7) y arilo, R4, R5 y R6 que pueden ser iguales o diferentes, cada uno representa un átomo de hidrogeno o un grupo alquilo (C1-6) lineal o ramificado, o R4 y R6 o R5 y R6 , junto con los átomos que los contienen, forman un anillo de imidazolidina o dihidrobencimidazol, sus isomeros opticos y sales de adicion de los mismos con un ácido farmacéuticamente aceptable, se entiende que un heterociclo que contiene nitrogeno significa un grupo de 5 a 7 miembros monocíclico, saturado que contiene uno, dos o tres heteroátomos, uno de dichos heteroátomos es el átomo de nitrogeno y el(los) heteroátomos(s) adicional(es) opcionalmente presente(s) se selecciona(n) entre átomos de oxígeno, nitrogeno y azufre, y se entiende que la cadena heteroalquileno significa una cadena de alquileno (C1-6) lineal o ramificada en la cual se ha reemplazado un miembro -CH2-por un átomo de oxígeno o azufre. Medicamentos como inhibidores de la dipeptidil-peptidasa IV (DPPIV).
ARP020101090A 2001-03-28 2002-03-26 Compuestos de sulfonilo de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen AR033620A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0104142A FR2822826B1 (fr) 2001-03-28 2001-03-28 Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
AR033620A1 true AR033620A1 (es) 2003-12-26

Family

ID=8861608

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101090A AR033620A1 (es) 2001-03-28 2002-03-26 Compuestos de sulfonilo de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Country Status (24)

Country Link
US (1) US6716843B2 (es)
EP (1) EP1245568B1 (es)
JP (1) JP3761827B2 (es)
KR (1) KR100457725B1 (es)
CN (1) CN1166633C (es)
AR (1) AR033620A1 (es)
AT (1) ATE316080T1 (es)
AU (1) AU780373B2 (es)
BR (1) BR0200982A (es)
CA (1) CA2379197C (es)
DE (1) DE60208763T2 (es)
DK (1) DK1245568T3 (es)
EA (1) EA004591B1 (es)
ES (1) ES2256421T3 (es)
FR (1) FR2822826B1 (es)
HK (1) HK1050357B (es)
HU (1) HUP0201088A3 (es)
MX (1) MXPA02002720A (es)
NO (1) NO322895B1 (es)
NZ (1) NZ518035A (es)
PL (1) PL353084A1 (es)
PT (1) PT1245568E (es)
SI (1) SI1245568T1 (es)
ZA (1) ZA200202525B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946481B1 (en) * 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
GB0010183D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
WO2003002530A2 (en) * 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
CN1990468A (zh) 2001-06-27 2007-07-04 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
DE60221983T2 (de) 2001-06-27 2008-05-15 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
KR20040033048A (ko) * 2001-09-14 2004-04-17 미츠비시 웰파마 가부시키가이샤 티아졸리딘 유도체 및 이의 약학적 용도
WO2004043940A1 (en) * 2002-11-07 2004-05-27 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004050022A2 (en) * 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
KR20050122220A (ko) * 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
RU2006107553A (ru) * 2003-08-13 2007-09-20 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) * 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050065144A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
KR20130105741A (ko) 2003-11-17 2013-09-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
PL3738585T3 (pl) 2004-01-20 2023-04-17 Novartis Ag Preparat i sposób jego bezpośredniego prasowania
CN101618216B (zh) * 2004-01-20 2012-01-04 诺瓦提斯公司 直接压片配方和方法
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EA013427B1 (ru) * 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
WO2005118555A1 (en) * 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
AU2005267093B2 (en) * 2004-07-23 2009-10-01 Nuada Llc Peptidase inhibitors
JP2008524331A (ja) * 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MX2007011453A (es) * 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
WO2007017423A2 (en) * 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
KR101352588B1 (ko) * 2005-09-14 2014-01-17 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료용 디펩티딜 펩티다아제 억제제
ME02005B (me) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibitori dipeptidil peptidaze za lečenje dijabetesa
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CN101360723A (zh) * 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
JP2009531456A (ja) * 2006-03-28 2009-09-03 武田薬品工業株式会社 （ｒ）−３−アミノピペリジン二塩酸塩の調製
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
MEP27308A (en) 2006-04-11 2010-06-10 Arena Pharm Inc Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
EA017799B1 (ru) * 2006-09-13 2013-03-29 Такеда Фармасьютикал Компани Лимитед Применение 2-[6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил]-4-фторбензонитрила
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
CN101684088B (zh) * 2008-09-22 2011-05-11 天津药物研究院 氰甲基吡咯衍生物、其制备方法和用途
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
EP3267994A4 (en) 2015-03-09 2018-10-31 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
WO2018187350A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490379A3 (de) * 1990-12-13 1992-06-24 BERLIN-CHEMIE Aktiengesellschaft Diaminosäurederivate und pharmazeutische Zusammensetzungen
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV

Also Published As

Publication number Publication date
HK1050357B (zh) 2005-05-13
MXPA02002720A (es) 2004-11-12
NO20021542D0 (no) 2002-03-27
BR0200982A (pt) 2002-12-31
EP1245568B1 (fr) 2006-01-18
US6716843B2 (en) 2004-04-06
CN1166633C (zh) 2004-09-15
EP1245568A1 (fr) 2002-10-02
PT1245568E (pt) 2006-05-31
HUP0201088A3 (en) 2006-02-28
FR2822826B1 (fr) 2003-05-09
KR100457725B1 (ko) 2004-11-17
HK1050357A1 (en) 2003-06-20
DE60208763T2 (de) 2006-09-28
NZ518035A (en) 2003-11-28
KR20020077180A (ko) 2002-10-11
JP3761827B2 (ja) 2006-03-29
DE60208763D1 (de) 2006-04-06
CN1377879A (zh) 2002-11-06
ATE316080T1 (de) 2006-02-15
ES2256421T3 (es) 2006-07-16
FR2822826A1 (fr) 2002-10-04
NO20021542L (no) 2002-09-30
US20030087950A1 (en) 2003-05-08
NO322895B1 (no) 2006-12-18
DK1245568T3 (da) 2006-05-15
EA200200299A1 (ru) 2002-10-31
EA004591B1 (ru) 2004-06-24
SI1245568T1 (sl) 2006-04-30
PL353084A1 (en) 2002-10-07
CA2379197C (fr) 2007-04-10
ZA200202525B (en) 2002-10-24
HU0201088D0 (es) 2002-06-29
AU2935002A (en) 2002-10-03
JP2002363167A (ja) 2002-12-18
CA2379197A1 (fr) 2002-09-28
AU780373B2 (en) 2005-03-17
HUP0201088A2 (hu) 2002-12-28

Similar Documents

Publication Publication Date Title
AR033620A1 (es) Compuestos de sulfonilo de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR033295A1 (es) Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
ECSP078064A (es) NUEVOS DERIVADOS de 2,4-DIANILINOPIRIMIDINAS, SU PREPARACIÓN, COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y PRINCIPALMENTE COMO INHIBIDORES DE IKK
CO5680403A2 (es) Antagonistas de mchr1r
NI201000022A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
ECSP088150A (es) Inhibidores macrociclicos del virus de la hepatitis c
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR041883A1 (es) Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR053453A1 (es) Derivados de aminoalquil- y amidoalquil-benzopirano substituidos
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR041882A1 (es) Compuestos de imidazopiridina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
AR059282A1 (es) Derivados del acido 1,3-dihidro-2h-benzo[f]isoindol acetico, metodo de preparacion, composiciones farmaceuticas que los contienen y usos terapeuticos como agonistas de receptores ep4.
AR069643A1 (es) Derivados diazenidiolatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR040570A1 (es) Deriados de acilaminotiazol, su preparacion y su aplicacion en terapeutica
AR050032A1 (es) Derivados de acido benzoico como inhibidores no nucleosidos de la transcriptasa inversa
AR072103A1 (es) Derivados de (piperazinilo con enlaces puente)-1- alcanona, su utilizacion como inhibidores de p75 y composiciones farmaceuticas que los contienen
AR050718A1 (es) Co-cristales entre polietilenglicolesy 5-fenilpirazolil-1-bencensulfonamidas. procesos de obtencion y composiciones farmaceuticas.
AR054120A1 (es) Compuestos de fenilpiridilpiperazina, procedimiento de preparacion, composiciones farmaceuticas que los contienen, y usos farmacologicos como antagonistas de receptores histaminergicos h3
AR043691A1 (es) Compuestos de azepina triciclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure